India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution
- Serum Institute of India's (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated with SII's licensed version of AstraZeneca Plc's AZN 1.21% COVID-19 vaccine.
- "I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said on Twitter.
- India's Ministry of External Affairs has raised Covishield's lack of recognition by the European Medicines Agency (EMA).
- The EMA said the only COVID-19 vaccine from AstraZeneca for which a marketing authorization application had been submitted and evaluated was Vaxzevria.
- Covishield does not currently have marketing authorization in the EU, even though it may use a similar production technology to Vaxzevria, the agency said.
- In addition to the AstraZeneca shot in the region, the other EU-recognized vaccines are those made by Moderna Inc MRNA 1.36%, Pfizer Inc PFE 0.44% - BioNTech SE BNTX 0.69%, and Johnson & Johnson JNJ 0.13%.
- A European Union vaccine passport program will allow people to travel freely within the bloc from July 1, as long as they have had one of four Western-made vaccines.
- In April, Reuters reported that the EU was seeking 10 million Covishield doses from SII to meet a shortfall before India halted all exports amid a domestic infection surge.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.